Related Experiment Videos
[Juvenile malignant lymphomas. 2 Non-Hodgkin lymphomas]
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1981
Summary
This study on pediatric Non-Hodgkin lymphomas (NHL) found that advanced stages (III-IV) and specific types like Burkitt-type had lower remission rates. Early stages and unclassified lymphoblastic NHL showed better outcomes.
Area of Science:
- Pediatric Oncology
- Hematology
- Immunology
Context:
- Non-Hodgkin lymphomas (NHL) in children present diagnostic and therapeutic challenges.
- Treatment outcomes vary significantly based on disease stage and histological subtype.
- Understanding surface markers aids in classifying and predicting NHL behavior.
Purpose:
- To analyze treatment outcomes for pediatric Non-Hodgkin lymphomas (NHL) based on histological classification and disease stage.
- To correlate histological subtypes (e.g., Burkitt-type, convoluted cell) and Ann Arbor staging with remission rates.
- To evaluate the effectiveness of combined therapy including irradiation, chemotherapy, and surgery.
Summary:
- A cohort of 33 children (ages 2-15) with NHL were treated between 1970-1978.
- Histological classification (Kiel) and surface markers were assessed alongside Ann Arbor staging.
- Therapies included irradiation, chemotherapy, and surgery; 3-year remission rates were 50% for stages I-II and 20% for stages III-IV.
Impact:
- Early-stage pediatric NHL and unclassified lymphoblastic subtypes demonstrated better 3-year remission rates (42%) compared to advanced stages.
- Convoluted cell and Burkitt-type NHL showed poorer prognoses with lower remission rates (16% and 27%, respectively).
- Findings highlight the importance of histological subtype and stage in predicting treatment response for childhood NHL.